Kancera AB (publ) (KAN.ST)
SEK 1.19
(-1.98%)
SEK 1.19
(-1.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -45.69 Million SEK | 51.98% |
| 2022 | -95.14 Million SEK | 10.2% |
| 2021 | -105.95 Million SEK | -97.36% |
| 2020 | -53.68 Million SEK | -965.08% |
| 2019 | 6.2 Million SEK | 130.47% |
| 2018 | -20.36 Million SEK | 17.97% |
| 2017 | -24.82 Million SEK | 54.77% |
| 2016 | -54.89 Million SEK | -290.25% |
| 2015 | -14.06 Million SEK | 34.49% |
| 2014 | -21.47 Million SEK | -70.19% |
| 2013 | -12.61 Million SEK | -16487.01% |
| 2012 | 77 Thousand SEK | 100.59% |
| 2011 | -13.16 Million SEK | -100.26% |
| 2010 | -6.57 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -31.01 Million SEK | 32.13% |
| 2024 Q2 | -75.7 Million SEK | -144.09% |
| 2023 Q2 | -66.97 Million SEK | 12.03% |
| 2023 Q4 | -45.69 Million SEK | 21.52% |
| 2023 Q1 | -76.13 Million SEK | 19.99% |
| 2023 FY | -45.69 Million SEK | 51.98% |
| 2023 Q3 | -58.22 Million SEK | 13.07% |
| 2022 Q1 | -96.72 Million SEK | 8.71% |
| 2022 Q3 | -68.22 Million SEK | 17.09% |
| 2022 FY | -95.14 Million SEK | 10.2% |
| 2022 Q2 | -82.28 Million SEK | 14.93% |
| 2022 Q4 | -95.14 Million SEK | -39.47% |
| 2021 Q4 | -105.95 Million SEK | 10.4% |
| 2021 Q2 | -129.5 Million SEK | -187.97% |
| 2021 Q3 | -118.25 Million SEK | 8.68% |
| 2021 FY | -105.95 Million SEK | -97.36% |
| 2021 Q1 | -44.97 Million SEK | 16.23% |
| 2020 Q2 | -56 Million SEK | -1913.99% |
| 2020 FY | -53.68 Million SEK | -965.08% |
| 2020 Q1 | -2.78 Million SEK | -144.81% |
| 2020 Q3 | -46.84 Million SEK | 16.37% |
| 2020 Q4 | -53.68 Million SEK | -14.61% |
| 2019 FY | 6.2 Million SEK | 130.47% |
| 2019 Q3 | 4.69 Million SEK | 1511.11% |
| 2019 Q2 | -333 Thousand SEK | 95.04% |
| 2019 Q1 | -6.71 Million SEK | 67.05% |
| 2019 Q4 | 6.2 Million SEK | 32.07% |
| 2018 FY | -20.36 Million SEK | 17.97% |
| 2018 Q4 | -20.36 Million SEK | 35.87% |
| 2018 Q2 | -52.7 Million SEK | -254.21% |
| 2018 Q1 | -14.87 Million SEK | 40.07% |
| 2018 Q3 | -31.75 Million SEK | 39.74% |
| 2017 Q1 | -45.46 Million SEK | 17.18% |
| 2017 Q3 | -43.21 Million SEK | 15.6% |
| 2017 Q2 | -51.2 Million SEK | -12.62% |
| 2017 FY | -24.82 Million SEK | 54.77% |
| 2017 Q4 | -24.82 Million SEK | 42.55% |
| 2016 Q3 | -60.59 Million SEK | 11.78% |
| 2016 FY | -54.89 Million SEK | -290.25% |
| 2016 Q4 | -54.89 Million SEK | 9.4% |
| 2016 Q2 | -68.68 Million SEK | -639.91% |
| 2016 Q1 | -9.28 Million SEK | 34.01% |
| 2015 Q4 | -14.06 Million SEK | 24.59% |
| 2015 Q1 | -16.3 Million SEK | 24.05% |
| 2015 FY | -14.06 Million SEK | 34.49% |
| 2015 Q2 | -23.85 Million SEK | -46.24% |
| 2015 Q3 | -18.65 Million SEK | 21.79% |
| 2014 Q2 | -27.76 Million SEK | -68.94% |
| 2014 FY | -21.47 Million SEK | -70.19% |
| 2014 Q4 | -21.47 Million SEK | 9.28% |
| 2014 Q3 | -23.67 Million SEK | 14.75% |
| 2014 Q1 | -16.43 Million SEK | -30.24% |
| 2013 Q3 | -553 Thousand SEK | 77.63% |
| 2013 Q4 | -12.61 Million SEK | -2181.74% |
| 2013 FY | -12.61 Million SEK | -16487.01% |
| 2013 Q1 | -5.31 Million SEK | -7003.9% |
| 2013 Q2 | -2.47 Million SEK | 53.5% |
| 2012 Q3 | -5.39 Million SEK | 59.32% |
| 2012 Q4 | 77 Thousand SEK | 101.43% |
| 2012 FY | 77 Thousand SEK | 100.59% |
| 2012 Q2 | -13.25 Million SEK | -4.89% |
| 2012 Q1 | -12.63 Million SEK | 4.02% |
| 2011 Q2 | -26.81 Million SEK | 22.12% |
| 2011 Q3 | -26.49 Million SEK | 1.17% |
| 2011 Q4 | -13.16 Million SEK | 50.33% |
| 2011 FY | -13.16 Million SEK | -100.26% |
| 2011 Q1 | -34.42 Million SEK | -423.8% |
| 2010 Q4 | -6.57 Million SEK | -88.09% |
| 2010 FY | -6.57 Million SEK | 0.0% |
| 2010 Q3 | -3.49 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | -37.627% |
| Biovica International AB (publ) | -58.73 Million SEK | 22.209% |
| Cantargia AB (publ) | -139.74 Million SEK | 67.304% |
| CombiGene AB (publ) | -101.44 Million SEK | 54.957% |
| Cyxone AB (publ) | -16.67 Million SEK | -174.097% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1437.416% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -55.505% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 18.241% |
| Fluicell AB (publ) | -2.76 Million SEK | -1553.71% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 86.115% |
| Mendus AB (publ) | -96.29 Million SEK | 52.549% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 66.925% |
| I-Tech AB | -83.26 Million SEK | 45.123% |
| Intervacc AB (publ) | -88.16 Million SEK | 48.172% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -43.114% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 185.85% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -139.727% |
| OncoZenge AB (publ) | -12.62 Million SEK | -261.86% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 8.495% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 127.513% |
| Lipum AB (publ) | -8.46 Million SEK | -439.776% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 8.654% |
| Ziccum AB (publ) | -2.13 Million SEK | -2038.138% |
| BioArctic AB (publ) | -606.58 Million SEK | 92.467% |
| Genovis AB (publ.) | -43.94 Million SEK | -3.985% |
| Camurus AB (publ) | -1.16 Billion SEK | 96.079% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 45.438% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -16.023% |
| Aptahem AB (publ) | 2.9 Million SEK | 1670.905% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 86.304% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 64.715% |
| Saniona AB (publ) | 40.44 Million SEK | 212.968% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -1.05% |
| AcouSort AB (publ) | -23.98 Million SEK | -90.494% |
| Xintela AB (publ) | -7.8 Million SEK | -485.12% |
| Abliva AB (publ) | -57.24 Million SEK | 20.175% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 44.415% |
| Amniotics AB (publ) | -5.63 Million SEK | -711.293% |
| 2cureX AB (publ) | -13.4 Million SEK | -240.909% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2014.391% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 946.148% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 133.919% |
| Biosergen AB | -1.88 Million SEK | -2326.553% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 322.779% |
| Corline Biomedical AB | -17.01 Million SEK | -168.587% |
| NextCell Pharma AB | -46.79 Million SEK | 2.348% |
| Nanologica AB (publ) | -9.38 Million SEK | -386.706% |
| LIDDS AB (publ) | -13.51 Million SEK | -238.159% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 76.532% |
| BioInvent International AB (publ) | -236.3 Million SEK | 80.664% |
| SynAct Pharma AB | -61.75 Million SEK | 26.014% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -113.364% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -245.388% |
| Alzinova AB (publ) | -21.22 Million SEK | -115.264% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -119.747% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 31.721% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -781.928% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 45.437% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -4850.379% |
| Simris Alg AB (publ) | 85.07 Million SEK | 153.708% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 44.336% |